IceCure up after FDA panel backs use of its breast cancer treatment system

Icecure Medical

08/11/2024 13:28

** Shares of Israel-based medical device maker IceCure
Medical  ICCM.O  rise 8.11% to 79 cents premarket
    ** A panel of experts to the FDA supported the use of
IceCure's system when used according to the proposed indications
for the treatment of patients with a type of breast cancer
    ** ICCM's ProSense provides a minimally invasive treatment
option to destroy tumors by freezing them
    ** 9 panelists voted in favor and 5 voted against the
benefit-risk profile of the system
    ** FDA is not obligated to follow the panel's decision, but
usually does
    ** Co expects FDA's decision by Q1 2025
    ** Up to last close, stock down ~31% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))